Winning Bizness Desk

Mumbai. Indian companies are writing new chapters all over the world. Mankind Pharma, the country's fourth largest pharmaceuticals company, which has written a new history of marketing and profit with the 'Manforce Condom' brand, may soon acquire a vaccine company. The 'Manforce Condom' maker is now going to challenge Dubai and the company can now acquire a big vaccine manufacturing company. In this deal, it is going to give a tough challenge to Dubai. The reason for this is that a consortium of Abu Dhabi Investment Authority and EQT also wishes to buy this vaccine company. According to the sources, privy to the development, Mankind Pharma has completed preparations to acquire BSV Group. Earlier this company was named Bharat Serum and Vaccines. Currently this company is owned by Advent International which bought 74 percent stake in this company from the Daftari family in 2019. After this, Advent International also bought the remaining stake in 2022.

Rs 14,000 crore deal

Sources have said that Mankind Pharma may make a deal of Rs 14,000 crore to buy vaccine company BSV Group. Reports have suggested that all the talks of this deal have been done and its official announcement can be made in a day or two. However, nothing has been said about this by Mankind Pharma and Advent International yet. At the same time, the consortium of Abu Dhabi Investment Authority (ADIA) and EQT of the United Arab Emirates (UAE) have also shown interest in buying BSV Group. While there was also an offer of a third bid for this deal, which was to be placed by the consortium of Warburg Pincus, Chrys Capital and Mubadala, but this bid was not submitted till the last moment.